With every passing day, new discoveries are made that lend support to the increasing and important role biomarker analysis and tumor profiling play in personalized cancer care. Caris Life Sciences® is actively participating in research to advance the understanding of molecular science, further enabling the delivery of precision medicine.

Poly Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine placebo versus gemcitabine evofosfamide and identifies candidate targets

Pathogenic somatic mutation (SM) of mismatch repair (MMR) genes and associations with microsatellite instability (MSI), tumor mutational burden (TMB) and SM in other DNA repair pathways in 24,223 tumor genomic profiles

Circadian clock protein (PER1) mutations in colorectal cancer (CRC)

Incidence of Neuregulin1 (NRG1) gene fusions across tumor types

Comprehensive molecular profiling of paired patient samples of primary and metastatic pancreatic ductal adenocarcinoma

Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC)

Molecular characterization of appendiceal cancer and comparison with right-sided and left-sided colorectal cancer

Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Impact of MLH1, PMS2, MSH2 and MSH6 alterations on TMB and PD-L1 expression in 1,057 MSI-H tumors

Mutational Complexity Increases in Lung Adenocarcinoma with the Development of Brain Metastasis